#China #Chengdu #Tuberculosis #Malaria #HitGen

HitGen Secures Funding for Critical Drug Discoveries

HitGen Inc., a prominent name in drug discovery, has taken a significant step forward by signing a new contract with the Bill and Melinda Gates Foundation. This partnership aims to utilize HitGen's advanced DNA-encoded library (DEL) technology to identify groundbreaking drug candidates for underserved diseases, particularly tuberculosis and malaria. Additionally, the agreement focuses on discovering innovative agents for non-hormonal contraception.

Strengthening Collaborative Efforts

With the funding provided by the Gates Foundation, HitGen will undertake DEL screening against 15 specific drug targets that have been identified in collaboration with key academic and research partners. The continuum of this project builds on previous successful efforts where HitGen was instrumental in identifying promising drug leads for malaria and tuberculosis. According to Dr. Jin Li, the Chairman and CEO of HitGen, this ongoing collaboration signifies their commitment to addressing unmet medical needs and engaging with leading philanthropic organizations.

HitGen’s Position in Drug Discovery

As a pioneer in DEL technology, HitGen has access to an extensive library boasting over 1.2 trillion distinct small molecules. This vast resource not only enhances the efficiency of the drug discovery process but also positions the company as a formidable player in the industry. The ability to conduct effective screenings allows HitGen to support various organizations globally in their drug discovery initiatives.

Technology Platforms at Work

Headquartered in Chengdu, China, HitGen extends its influence with subsidiaries in Cambridge, UK, and Houston, USA. The company has established multiple technology platforms to facilitate the discovery and refinement of both small molecule and nucleic acid-based drugs. Among these technologies, the world-leading DEL, along with fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies, stand out. These platforms, coupled with emerging methodologies for oligonucleotide-based therapeutics (OBT) and targeted protein degradation technology (TPD), empower HitGen to keep delivering impactful solutions.

A Vision for the Future

Looking ahead, HitGen aims to enhance its capabilities further with its DEL+AI+Automated DMTA (Design-Make-Test-Analyze) molecular optimization platform, which is set to accelerate the development of preclinical candidate compounds. This strategic vision is supported by a range of flexible collaboration models that have already resulted in numerous partnerships with biopharmaceutical research entities around the world.

In summary, HitGen Inc.'s recent funding agreement with the Gates Foundation marks a crucial milestone in the quest to tackle tuberculosis and malaria. As HitGen continues to drive innovation in drug discovery, it contributes significantly to the global effort to combat diseases that disproportionately affect underserved populations. With a clear focus on transformative solutions, the future looks promising for both HitGen and the patients who stand to benefit from these groundbreaking developments.